Sep 1, 1980

CCNU chemotherapy in adult patients with tumors of the basal ganglia and brain stem

Journal of Neurosurgery
A PompiliM Fontana

Abstract

The present investigation evaluates those few patients of our series with basal ganglia and brain-stem tumor who refused either surgical decompression and biopsy or radiation therapy. Four patients were suffering from tumors of the basal ganglia and three from brain-stem tumors; all the tumors were diagnosed by classical neuroradiological investigations and computerized tomography. The patients were given CCNU by mouth, 13 mg/sq m every 6 weeks. No toxicity was recorded. Mean survival was 19 weeks for patients with basal ganglia tumors and 48 weeks for those with brain-stem tumors. All patients were evaluated with respect to the quality of survival. Results were compared with those obtained in a control group of patients who received methylprednisolone therapy only.

Mentioned in this Paper

TNM Staging System
Neoplasms
X-Ray Computed Tomography
Malignant Neoplasm of Brain Stem
Belustine
Entire Basal Nuclei
Lenticulostriate Disorders
Nitrosourea Compounds
Radiotherapeutic
Biopsy

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.